Solasia Pharma KK (4597) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

RaQualia Pharma, Inc.

Wakamoto Pharmaceutical Co., Ltd.

Noile-Immune Biotech, Inc.

Solasia Pharma KK

Fuso Pharmaceutical Industries Ltd.

Healios KK

Taiko Pharmaceutical Co., Ltd.

SymBio Pharmaceuticals Ltd.

Nippon Chemiphar Co., Ltd.

CanBas Co., Ltd.

BrightPath Biotherapeutics Co., Ltd.

Why is Solasia Pharma KK ?

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -229.10

Poor long term growth as Operating profit has grown by an annual rate 12.40% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -229.10
The company has reported losses. Due to this company has reported negative ROE

Poor long term growth as Operating profit has grown by an annual rate 12.40% of over the last 5 years

Flat results in Mar 26

OPERATING CASH FLOW(Y) Lowest at JPY -1,121 MM
INTEREST(Q) At JPY 4 MM has Grown at 300%
RAW MATERIAL COST(Y) Grown by 420.54% (YoY)

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -25.00%, its profits have risen by 53.6%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Solasia Pharma KK for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Solasia Pharma KK

-100.0%

0.25

62.44%

Japan Nikkei 225

59.79%

2.03

29.50%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

1.06%

EBIT Growth (5y)

12.40%

EBIT to Interest (avg)

-218.37

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.23

Sales to Capital Employed (avg)

0.21

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.68

EV to EBIT

-5.47

EV to EBITDA

-5.70

EV to Capital Employed

27.94

EV to Sales

11.59

PEG Ratio

Dividend Yield

ROCE (Latest)

-510.59%

ROE (Latest)

-52.17%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

16What is working for the Company

NET SALES(HY)

Higher at JPY 344 MM

NET PROFIT(HY)

Higher at JPY -457 MM

DEBTORS TURNOVER RATIO(HY)

Highest at 19.52 times

-17What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at JPY -1,121 MM

INTEREST(Q)

At JPY 4 MM has Grown at 300%

RAW MATERIAL COST(Y)

Grown by 420.54% (YoY

NET SALES(Q)

Lowest at JPY 6 MM

OPERATING PROFIT(Q)

Lowest at JPY -296 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -4,933.33 %

PRE-TAX PROFIT(Q)

Lowest at JPY -307 MM

NET PROFIT(Q)

Lowest at JPY -307 MM

Here's what is working for Solasia Pharma KK

Debtors Turnover Ratio

Highest at 19.52 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Depreciation

At JPY 9 MM has Grown at 50%

period on period (QoQ)

MOJO Watch

The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (JPY MM)

Here's what is not working for Solasia Pharma KK

Net Sales

At JPY 6 MM has Fallen at -76%

Year on Year (YoY)

MOJO Watch

Near term sales trend is extremely negative

Net Sales (JPY MM)

Interest

At JPY 4 MM has Grown at 300%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Operating Cash Flow

Lowest at JPY -1,121 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (JPY MM)

Net Sales

Lowest at JPY 6 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (JPY MM)

Operating Profit

Lowest at JPY -296 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (JPY MM)

Operating Profit Margin

Lowest at -4,933.33 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at JPY -307 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (JPY MM)

Net Profit

Lowest at JPY -307 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (JPY MM)

Raw Material Cost

Grown by 420.54% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales